Home / Recalls / Teva Pharmaceuticals USA, Inc / D-0127-2024

D-0127-2024 Class III Terminated

Recalled by Teva Pharmaceuticals USA, Inc — Parsippany, NJ

Recall Details

Product Type
Drugs
Report Date
December 6, 2023
Initiation Date
November 10, 2023
Termination Date
June 3, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity

Product Description

Testosterone Gel, 1.62% CIII (Alcohol 80% v/v), packaged in 30 unit-dose packets per carton, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0591-2926-30

Reason for Recall

OOS for viscosity

Distribution Pattern

USA nationwide

Code Information

Lot #: 100029472, Exp. 2/29/2024

Other recalls by Teva Pharmaceuticals USA, Inc

  • D-0355-2026 Class II — Metoprolol Succinate Extended-Release Tablets, 50 mg, 100 tablets bottles (NDC: (January 29, 2026)
  • D-0356-2026 Class II — Metoprolol Succinate Extended-Release Tablets, Rx Only, 100 mg, 100 tablets bott (January 29, 2026)
  • D-0354-2026 Class II — Metoprolol Succinate Extended-Release Tablets, 25 mg, 100 tablets bottles (NDC: (January 29, 2026)
  • D-0357-2026 Class II — Metoprolol Succinate Extended-Release Tablets, 200 mg, 100 tablets bottles, Rx O (January 29, 2026)
  • D-0198-2026 Class III — Carton label: Testosterone Gel 1%, 2.5 grams per unit dose, CIII, 30 unit-dose p (November 7, 2025)
  • D-0151-2026 Class II — Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg pe (October 13, 2025)
  • D-0104-2026 Class II — Prazosin Hydrochloride, Capsules, USP, 1 mg, Rx only, Distributed by TEVA PHARMA (October 7, 2025)
  • D-0106-2026 Class II — Prazosin Hydrochloride, Capsules, USP, 5 mg, Rx only, Distributed by TEVA PHARMA (October 7, 2025)
  • D-0105-2026 Class II — Prazosin Hydrochloride, Capsules, USP, 2 mg, Rx only, Distributed by TEVA PHARMA (October 7, 2025)
  • D-0473-2025 Class II — Metoclopramide Tablets, USP 10 mg, 100-count bottle, Rx only, Manufactured in Cr (May 23, 2025)